Balanced Outlook for Fluor Corporation: Hold Rating Amidst Growth Potential and Near-Term Challenges
KeyBanc Maintains Applied Industrial Technologies(AIT.US) With Buy Rating
Buy Rating Affirmed for Insmed on Breakthrough Trials and Market Expansion Opportunities
J.P. Morgan Maintains Fabrinet(FN.US) With Hold Rating, Raises Target Price to $240
Fabrinet Analyst Ratings
JP Morgan Maintains Neutral on Fabrinet, Raises Price Target to $240
Insmed Analyst Ratings
Truist Financial Reaffirms Their Buy Rating on Insmed (INSM)
Brensocatib Poised for Market Success: A Buy Rating for Insmed Amid Positive KOL Sentiment and Limited Competition
Insmed (INSM) Receives a Buy From Morgan Stanley
Insmed Analyst Ratings
Insmed's Promising Outlook: Buy Rating Backed by Arikayce Performance and Brenso Launch Potential
Strong Arikayce Sales and Promising Clinical Advancements Bolster Buy Rating for Insmed
Analysts Offer Insights on Industrial Goods Companies: Rockwell Automation (ROK), FTAI Aviation (FTAI) and AerSale Corporation (ASLE)
Morgan Stanley Lowers Price Target on Abercrombie & Fitch to $155 From $172, Keeps Equalweight Rating
Buy Rating Affirmed for Vaxcyte Ahead of Key VAX-31 Phase 1/2 Milestone
Vaxcyte Analyst Ratings
TD Cowen Maintains Vaxcyte(PCVX.US) With Buy Rating
Optimistic Buy Rating for Vaxcyte Amidst Promising Vaccine Candidate Progress and Strategic Positioning
Fluor Analyst Ratings